Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation

Transplantation

Volumn 80, Issue 6, 2005, Pages 859-864

  Jain, Ashokkumar ^a,b,c,d   Vekatramanan, Raman ^c   Eghtesad, Bijan ^b   Gadomski, Mary ^b   Mohanka, Ravi ^a   Marcos, Amadeo ^b   Fung, John ^b  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Liver transplantation; Mycophenolate mofetil; Nephrotoxicity; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IOTALAMIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DETERIORATION; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGING; CREATINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ORGAN SIZE; SEX CHARACTERISTICS; SURVIVAL RATE; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 26644433876     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000173994.63299.63     Document Type: Article

References (19)

1. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344: 423.
2. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The US Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110.
3. Papatheodoridis GV, O'Beirne, I, Mistry P, et al. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68: 155.
4. Herrero JI, Quiroga J, Sangro B, et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999; 5: 414.
5. Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69: 1886.
6. Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186.
7. Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587.
8. Agarwala SCE, Jain A, McCauley J, et al. Evaluation of renal function in transplant patients on tacrolimus therapy. J Clin Pharmacol 2003; 42: 798.
9. Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988; 20: 498.
10. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1982; 2: 614.
11. McCaughan GW, Strasser S, Dolan P, Sheil AG. Liver allograft rejection: analysis of OKT3 rescue therapy. Transplant Proc 1992; 24: 2250.
12. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230: 441.
13. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001; 7: 623.
14. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934.
15. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
16. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321.
17. Jain AB VR, Gadomski M, Eghtesad B, et al. Use of mycophenolate mofetil (MMF) for tacrolimus-related, chronic nephrotoxicity in post liver transplant (LTX) patients: long-term prospective trial with minimum six years follow up. Liver Transplant 2003; 9: C43.
18. Jain AB FJ, Hamad I, Zuckerman S. Use of mycophenolate mofetil for tacrolimus related chronic nephrotoxicity in liver transplantation recipients. American Association for the Study of Liver Diseases. Hepatology 1997; 29: 235a.
19. Hodge EE, Reich DJ, Clavien PA, Kim-Schluger L. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. Transplant Proc 2002; 34: 1546.